GlassScriptPhysician profile
James A Whitaker
NPI 1750692562
$4,370.11
in general payments reported to CMS, 2019-2025
26 companies · $736 in 2025
The $736 reported for 2025 was more than what 84% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $278 · 2021: $828 · 2022: $631 · 2023: $726 · 2024: $844 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,804.98 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lilly USA, LLC | $439.60 | 2019-2024 | Reyvow, Emgality |
| Amgen INC. | $367.81 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $363.63 | 2019-2025 | Ajovy |
| Collegium Pharmaceutical, INC. | $201.66 | 2020-2021 | |
| Pfizer INC. | $176.48 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $174.12 | 2020-2022 | |
| Boston Scientific Corporation | $173.29 | 2024-2025 | Intracept |
| Nevro Corp. | $123.64 | 2023 | Senza |
| Biodelivery Sciences International, INC. | $78.02 | 2021 | |
| Stimwave Technologies Incorporated | $71.53 | 2019 | |
| Allergan, INC. | $48.35 | 2019-2021 | |
| Abbott Laboratories | $42.47 | 2023-2024 | Eterna, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.00 | 2023 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $31.01 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $29.10 | 2025 | Symbravo |
| Fidia Pharma USA INC. | $25.66 | 2019 | |
| Depuy Synthes Sales INC. | $25.05 | 2024 | Monovisc, Peak, Orthovisc |
| Medtronic, INC. | $21.56 | 2024 | Synchromedii |
| Sanofi-Aventis U.S. LLC | $20.85 | 2023 | |
| Averitas Pharma INC. | $20.81 | 2023 | Qutenza |
| Regeneron Healthcare Solutions, INC. | $20.73 | 2024 | Dupixent |
| Tersera Therapeutics LLC | $19.23 | 2025 | Prialt |
| Biohaven Pharmaceuticals, INC. | $18.38 | 2021 | |
| Bioventus LLC | $16.84 | 2023 | Gelsyn-3 |
| Scilex Pharmaceuticals INC. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Whitaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.